ASML's price target has been lowered by UBS from 900 euros to 710 euros, with a "Neutral" rating being maintained. This adjustment is a result of a weak order situation in the previous quarter and a lowered outlook for 2025.
Ongoing uncertainties for the years 2026 and 2027 were highlighted by analyst Francois-Xavier Bouvignies in a study published on October 16, 2024. UBS acknowledges that there is limited further downside risk despite the recent decline in share price. However, it may take time for investor confidence to recover as the market looks ahead to 2026.
The report emphasizes the cautious sentiment surrounding ASML's future performance given challenging market conditions.